Advanced Research & Technology Institute

Mayo Foundation for Medical Education and Research

Eberhard Karls Universitaet Tuebingen

Ludwig-maximilians-universitat Munchen Abeteilung Mediziniche Genetik

Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt

Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt Gmbh

Ludwig-maximilians-universitat Muchen

Ludwig-maximilians-universtat Munchen

Ludwig-maximilians-universitat Munchen Abteilung Medizinische Genetik

Ludwig-Maximilians-Universitat München

Eberhard-karls-universitat Tubingen

Tim Matthias Strom

Thomas Meitinger

Michael Econs

Ken W White

Elisabeth Kremmer

Matthew J Farrer

Marius Ueffing

Alexander Zimprich

Ryan Uitti

Zibigniew Wszolek

Mary M Hulihan

Sara J Lincoln

Jennifer M Kachergus

Nadja Patenge

Friedrich Asmus

Petra Herzig

Thomas Gasser

Christian Johannes Gloeckner

Saskia Biskup

Kenneth E White

Christian J Gloeckner

Petra Leitner

Ken White

The present invention relates to methods of diagnosing hypophosphatemic disorders.

Methods of diagnosing hypophosphatemic disorders

The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD.

KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders

The present invention relates to a kit for diagnosing a disorder comprising a reagent that detects FGF23 polypeptides and mutant FGF23 polypeptides.

Kits for diagnosing a hypophosphatemic disorder

Fibroblast growth factor (FGF23) polypeptides

The present invention relates to antibodies that bind to FGF23 polypeptides and to FGF23 mutant polypeptides.

Antibodies to fibroblast growth factor (FGF23)

The invention relates to novel nucleic acids encoding a fibroblast growth factor-23(FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprising inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The invention also relates to methods of treating osteoporosis, dermatomyositis, and coronary artery disease comprising stimulating the biological activity of FGF23 in a patient.

Fibroblast growth factor (FGF23) nucleic acids

Growing community of inventors

Munich, Germany

Tim Matthias Strom